Dr. Francisco Domínguez receives a grant from the Instituto Carlos III to fund a study on endocrine disruptors
The project, which will last three years, aims to study the impact of environmental toxic agents on female infertility
The study is planned to recruit 50 patients with endometriosis and 50 patients with implantation failure
The researcher from the IVI Foundation will receive state funding for the second time, in this case amounting to Euro 62,920
VALENCIA, APRIL 26, 2018
Dr. Francisco Domínguez, researcher at IVI Foundation, has received a grant from the Carlos III Institute to fund the project entitled “The Impact of Endocrine Disruptors on Human Endometrial Receptivity and its Relationship with Implantation and Endometriosis”. The study will continue for three years, during which time Dr. Dominguez will investigate the influence of endocrine disruptors (environmental toxic agents) on female fertility. Funding for this project amounts to Euro 62,920, and along with Francisco Domínguez, 8 additional IVI staff members will join the research team.
The impact of endocrine disruptors on human reproduction has been an area of focus for investigators at the IVI Foundation for several years. Dr. Domínguez has already conducted preliminary studies on this topic Furthermore, recent literature points to the exposure to endocrine disruptors as a factor associated with conditions related to assisted reproduction outcomes.
In this study, Dr. Dominguez will measure the levels of endocrine disruptors in samples from 50 patients with endometriosis and 50 patients with implantation failure, and determine if there are correlations. During the study, patients will complete a survey, where their lifestyle and potential exposure to environmental toxic agents will be assessed. Then, several types of biologic samples will be collected (blood, urine and follicular fluid). Within these three matrices, the following disruptors will be measured: bisphenol A, parabens, phthalates, soybean-derived phytoestrogens and heavy metals such as cadmium, mercury and lead.
As described by Dr. Domínguez “The long-term objective of the study is to monitor the impact of these endocrine disruptors on the female reproductive system and to improve fertility treatment outcome through lifestyle changes and in vitro therapeutic interventions.”
About IVI – RMANJ
IVI was set up in 1990 as the first medical institution in Spain to specialise exclusively in human reproduction. Since then it has helped more than 160,000 babies to be born, thanks to its use of the latest Assisted Reproduction Technologies. At the start of 2017, IVI merged with RMANJ to become the largest Assisted Reproduction group in the world. It currently has more than 70 clinics around the world and is a leader in Reproductive Medicine. https://ivi.es/ – http://www.rmanj.com/
For further information:
IVI. (+34) 963173610
Javier Ybarra Javier.email@example.com
Lucía Renau Lucia.firstname.lastname@example.org
Dori Argente Dori.email@example.com
Mar González Mar.firstname.lastname@example.org